UK NICE approves first mono-anti-Stelara targeting IL-12/IL-23 for treatment of ulcerative colitis

The National Institute for Health and Clinical Excellence (NICE) has approved Janssen's Stelaara (ustekinumab) for the treatment of adult patients with moderate to severe activeulcerative colitis(UC) adult patients who are unable to tolerate, underreact editing or lose response after treatmentStelara is the first biological therapy used to treat UC's targeted interleukin (IL)-12 and IL-23 cytokinesIL-12 and IL-23 play a key regulatory role in theresponse to inflammation andimmunityPhoto Source:Tumor Necrosis Factor (TNF) - Alpha Vidozumab is the most commonly used biologic for the treatment of UCStelara and Vidozumab have similar properties and differ from The Mechanism of Action of TNF-Alpha Inhibitorsclinical trials showed that Stelara was more effective than placebo in treating patients with moderate to severe active ulcerative colitisIndirect comparisons in the first eight weeks of treatment showed that Stelara may be more effective than TNF-alpha inhibitors, but there was no significant difference between the two biologics for maintenance therapyNICE has previously recommended the drug for the treatment of plaque-like psoriasis, psoriasis and Crohn's diseaseabout 146,000 people in the UK have UC, a chronic inflammatory disease that affects the rectum and the large intestine and is not yet curable